Ensuring that long-term follow-up agreements for gene therapy patients remain unencumbered despite economic or personnel changes is proving to be a question that may require multi-stakeholder creativity to answer, US Food and Drug Administration officials acknowledged.
Because gene therapies still are new and their long-term effects unknown, the agency wants sponsors to track recipients for up to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?